- Overview of HCC
- Key discussions: Child-Pugh scoring, BCLC staging
- Starting systemic therapy
- Key discussions: transitioning from locoregional to systemic therapy, determining what patients should be biopsied and what cases should go before a tumor board
- Selection of first-line therapy for advanced, unresectable HCC
- Therapeutic options for patients with HCC in the second-line setting
- Emerging investigational combinations and early data
- Mitigating adverse events and nuances of treatment administration
Date / Time
Anthony El-Khoueiry, MD
Associate Professor of Medicine
Division of Medical Oncology, Keck School of Medicine
Norris Comprehensive Cancer Center, University of Southern California
Los Angeles, California
Mark Yarchoan, Other
The Sidney Kimmel Comprehensive Cancer Center
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate recent findings into the treatment of patients with hepatocellular carcinoma.
This program is intended for oncologists, hepatologists, gastroenterologists, radiologists, and other healthcare providers who care for patients with advanced HCC.
Upon completion of this activity, participants should be able to:
- Explore the current status of predictive biomarkers for identification and selection of patients for novel therapies and emerging molecular/immunologic classifications that could inform future biomarker-enriched clinical trial design, enabling precision oncology care in HCC
- Select optimal, individualized locoregional treatment for patients with HCC based on recent advances and evolving best practices to maximize clinical outcomes
- Review recent therapeutic advances and FDA approvals of novel systemic treatments (including targeted and immunotherapeutic agents) for patients with newly diagnosed and relapsed/refractory advanced HCC and integrate this information into clinical practice
- Plan therapeutic strategies that optimize the selection/sequence of therapies to provide the best outcome to patients with HCC in the first-line setting and for patients with advanced HCC and treatment for patients with HCC that has progressed on or after 1 or multiple lines of therapy, taking into consideration the available clinical evidence, known agent toxicity/ tolerability profiles, expert recommendations, and patient preferences
- Assess the safety profiles of targeted therapies and checkpoint inhibitors used in the management of HCC
- Counsel patients to help them understand their treatment options and to be proactive, knowledgeable learners in their care
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.